Israel's Gamida Cell raises $40 million for bone marrow trial |  | TEL AVIV (Reuters) - Israel's Gamida Cell, which is developing cellular therapies to treat cancer and rare genetic diseases, said on Monday it raised $40 million to finance the advanced trial of its product NiCord to facilitate bone marrow transplants. |
|  |
Novartis throws down gauntlet to Roche with Rituxan copy |  | ZURICH (Reuters) - Switzerland's Novartis increased pressure on Roche's ageing stable of big-selling drugs on Monday by becoming the latest company to win European approval for a cut-price version of Rituxan for blood cancer and immunological diseases. |
|  |
|  |  | |  |  | Related Video |
|  | |  | |  |  |  |  |  | A quick-fix on the day's news delivered when you want it. Register Today |  |
|  |  |  | A daily digest of breaking business news, coverage of the US economy, major corporate news and the financial markets. Register Today |  |
|  | » » MORE NEWSLETTERS |  |
|